CA2145767A1 - Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments - Google Patents

Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments

Info

Publication number
CA2145767A1
CA2145767A1 CA002145767A CA2145767A CA2145767A1 CA 2145767 A1 CA2145767 A1 CA 2145767A1 CA 002145767 A CA002145767 A CA 002145767A CA 2145767 A CA2145767 A CA 2145767A CA 2145767 A1 CA2145767 A1 CA 2145767A1
Authority
CA
Canada
Prior art keywords
lys
leu
ser
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002145767A
Other languages
English (en)
French (fr)
Inventor
Rampratap S. Kushwaha
Henry C. Mcgill, Jr.
Patrick Kanda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Biomedical Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2145767A1 publication Critical patent/CA2145767A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002145767A 1993-08-04 1994-08-02 Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments Abandoned CA2145767A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10216093A 1993-08-04 1993-08-04
US08/102,160 1993-08-04

Publications (1)

Publication Number Publication Date
CA2145767A1 true CA2145767A1 (en) 1995-02-16

Family

ID=22288420

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002145767A Abandoned CA2145767A1 (en) 1993-08-04 1994-08-02 Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments

Country Status (6)

Country Link
EP (1) EP0664813A4 (ja)
JP (1) JPH08502525A (ja)
KR (1) KR950703580A (ja)
AU (1) AU683295B2 (ja)
CA (1) CA2145767A1 (ja)
WO (1) WO1995004755A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0831881T3 (da) 1995-06-06 2003-07-07 Avant Immunotherapeutics Inc CETP til forøgelse af HDL-cholesterolniveau
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
EP0618803A4 (en) * 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.

Also Published As

Publication number Publication date
EP0664813A1 (en) 1995-08-02
KR950703580A (ko) 1995-09-20
JPH08502525A (ja) 1996-03-19
EP0664813A4 (en) 1998-05-27
AU7552694A (en) 1995-02-28
WO1995004755A1 (en) 1995-02-16
AU683295B2 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
US5519001A (en) CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
US5512548A (en) CETP inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
JP5613890B2 (ja) アテローム性動脈硬化症の治療のためのペプチドに基づいた免疫治療、及び酸化した低密度リポ蛋白質に対する免疫応答の測定のためのペプチドベースのアッセーの開発
Putnam et al. Alpha, Beta, Gamma
Bara et al. Oncofetal mucin Ml epitope family: characterization and expression during colonic carcinogenesis
US5437864A (en) Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
Reimert et al. Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay
US20090226454A1 (en) Antibodies against a peptide epitope of apoliporotein b
Vallance-Owen et al. Studies on insulin antagonism in plasma
IE62702B1 (en) Polypeptide analogs of apolipoprotein e, diagnostic systems and methods using the analogs
Jarrett et al. Direct method for detection and characterization of cell surface receptors for insulin by means of 125I-labeled autoantibodies against the insulin receptor.
KR100204738B1 (ko) 콜레스테릴 에스테르 전달 단백질 저해 펩티드 및 이를 포함하는 동맥경화증 예방 및 치료제
JP3534748B2 (ja) Ｔｎｆ及び／またはｌｐｓ毒性を抑制するペプチド
US6153195A (en) Method of delivering drugs to cells specific for an HL-60 lectin
Jorde et al. Fasting and postprandial plasma GIP values in man measured with seven different antisera
Iferroudjene et al. Evidence for an active hydrophobic form of factor H that is able to induce secretion of interleukin 1‐β or by human monocytes
CA2145767A1 (en) Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
EP0842269A1 (en) Mocarhagin, a cobra venom protease, and therapeutic uses thereof
AU643685B2 (en) Parathyroid hypertensive factor
Bach et al. Plasma β-endorphin during clinical and experimental ischaemic pain
Westermark et al. A Protein AA-Variant Derived from a Novel Serum AA Protein, SAA1 δ, in an Individual from Papua New Guinea
EP1093462B1 (en) Compound capable of inhibiting the binding of a protein to mast cells, use of the compound for the preparation of a drug, a pharmaceutical composition, a method of diagnosing a disease, and a method of selection
US5192664A (en) Parathyroid hypertensive factor, antibodies and uses thereof
NISHIMURA et al. Heterogeneity of free alpha-subunit in term placenta
WO1997017371A1 (en) ISOLATION OF apo(a), COMPOSITIONS, AND METHODS OF USE

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20010802